Previous 10 | Next 10 |
iBio, Inc. (IBIO) Q2 2022 Earnings Conference Call February 14, 2022 16:30 ET Company Participants Stephen Kilmer - Investor Relations Tom Isett - Chairman and Chief Executive Officer Martin Brenner - Chief Scientific Officer Rob Lutz - Chief Financial and Business Officer Conference Call Par...
iBio press release (NYSE:IBIO): FQ2 GAAP EPS of -$0.05 misses by $0.01. Revenue of $0.17M (-76.1% Y/Y) misses by $0.08M. Shares -0.85%. As of December 31, 2021, iBio had cash and cash equivalents plus debt securities of approximately $57.4 million, excluding $5.9 million of restricted cash. T...
BRYAN, Texas, Feb. 14, 2022 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a developer of next-generation biopharmaceuticals and pioneer of the sustainable FastPharming Manufacturing System ® , today announces its fina...
AAP, AEMD, AMKR, ANET, ASYS, BKD, CAR, CIDM, CLR, OTCQB:ELTP, OTCQB:GAXY, HE, IBIO, KRG, MEDP, OMCL, OTTR, POWW, PRI, SCI, SRC, STEM, TNET, VNO, WTER, ZD For Seeking Alpha's full earnings season calendar, click here. For further details see: Notable earnings after Monday's close
iBio (NYSE:IBIO) is scheduled to announce Q2 earnings results on Monday, February 14th, after market close. The consensus EPS Estimate is -$0.04 (flat Y/Y) and the consensus Revenue Estimate is $0.25M (-64.8% Y/Y). Over the last 3 months, EPS estimates have seen 1 upward revision and 0 downwa...
BRYAN, Texas, Feb. 07, 2022 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a developer of next-generation biopharmaceuticals and pioneer of the sustainable, plant-based FastPharming Manufacturing System ® , announced t...
AAP, ACTG, AESE, OTCPK:AOIFF, DADAASTS, ATHX, AXON, AYTU, BIOC, BITF, CIDM, CMP, OTCQX:CWBHF, CWBR, CWCO, CYBN, DM, DNMR, DRIO, OTCQB:ELTP, ETON, EVFM, GLAD, GNLN, GOEV, IBIO, IDEX, INPX, IONQ, ISUN, LCID, LUNA, MARK, OTCQX:MRMD, MVST, NDRA, NEPT, PLBY, POWW, PRCH, PRPO, QFIN, RKDA,...
BRYAN, Texas, Jan. 26, 2022 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a developer of next-generation biopharmaceuticals and pioneer of the sustainable FastPharming Manufacturing System ® , today shared an update o...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Vaxart (NASDAQ: VXRT ) is a clinical-stage biotech company focused on commercializing orally-delivered vaccines. VXRT stock has been volatile in 2021, thanks to hopes and setbacks related to its potential Covid-1...
BRYAN, Texas, Jan. 04, 2022 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a developer of next-generation biopharmaceuticals and pioneer of the sustainable, plant-based FastPharming Manufacturing System ® , today annou...
News, Short Squeeze, Breakout and More Instantly...
– The sale of the facility eliminates $13.2M of secured debt – – Completes iBio’s transition to an AI and precision biologics innovation company - SAN DIEGO, June 03, 2024 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or th...
2024-05-28 07:30:05 ET Chardan Capital analyst issues BUY recommendation for IBIO on May 28, 2024 05:34AM ET. IBIO was trading at $2.19 at issue of the analyst recommendation. The overall analyst consensus : HOLD. Current analyst recommendations are : 1 - Hold recommenda...
Strengthened cash position with investment by healthcare specialist investors Expanding into cardio-metabolic space through AstralBio collaboration BRYAN, Texas and SAN DIEGO, May 13, 2024 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company...